mTOR Inhibitor Treatment for Keratin Hyperproliferation Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Keratin hyperproliferation disorders, such as psoriasis, pachyonychia congenita, and hyperhidrosis, lack effective treatments, with current therapies primarily focusing on symptom alleviation rather than addressing the underlying keratin overexpression.
Innovation Solution
Administering a therapeutically effective amount of an mTOR inhibitor, such as rapamycin, to inhibit the expression of inducible keratins like K6a and K17, which are overexpressed in these disorders, by targeting the mTOR signaling pathway to reduce protein synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current symptom-focused treatments are used for keratinhyperproliferation disorders, then quality of life is partially improved, but the underlying keratin overexpression remains untreated
Solution Approach 1:
The patent applies preliminary action by targeting the upstream mTOR signaling pathway that controls keratin gene expression. By inhibiting mTOR before keratin overexpression occurs, the treatment prevents the development of hyperproliferation disorders rather than merely treating symptoms after they manifest. This is achieved through compounds that block mTOR kinase activity, thereby preemptively stopping the pathological cascade.
Solution Approach 2:
The patent extracts and targets the specific molecular mechanism (mTOR signaling pathway) that drives keratin hyperproliferation. By isolating and inhibiting this particular pathway with selective mTOR inhibitors, the treatment addresses the root cause of the disorder rather than applying broad-spectrum symptom management. This selective extraction of the pathological mechanism enables precise therapeutic intervention.
2Reliability
If mTOR inhibitors are administered to treat keratinhyperproliferation disorders, then keratin overexpression is reduced, but potential side effects from pathway inhibition may occur
Solution Approach 1:
The patent applies local quality by designing mTOR inhibitors with selective action on keratin-expressing cells rather than systemic inhibition. The compounds are engineered to target specific tissue contexts where keratin hyperproliferation occurs, thereby limiting off-target effects and reducing side effects while maintaining curative efficacy in the affected tissues.
Solution Approach 2:
The patent employs partial action by using mTOR inhibitors at doses and durations sufficient to reduce keratin overexpression but not so high as to cause excessive pathway suppression. This controlled partial inhibition achieves therapeutic effect while minimizing disruption to normal physiological functions that also depend on mTOR signaling.
3Device complexity
If traditional symptom management therapies are used, then treatment complexity remains low, but therapeutic effectiveness is limited
Solution Approach 1:
The patent applies parameter changes by shifting the therapeutic target from downstream symptoms to upstream molecular parameters (mTOR kinase activity, keratin gene expression). This change in therapeutic parameter from symptomatic to mechanistic targeting transforms the treatment approach, enabling more effective intervention while maintaining reasonable treatment complexity through oral or topical administration of small molecule inhibitors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mTOR inhibitor treatment effectively reduces pain scores and improves quality of life by decreasing keratin hyperproliferation, as demonstrated by clinical improvements in patients with pachyonychia congenita, with significant reductions in plantar hyperkeratosis and associated pain.
Implementation Method 1
Administering a therapeutically effective amount of an mTOR inhibitor, such as rapamycin, to inhibit the expression of inducible keratins like K6a and K17, which are overexpressed in these disorders, by targeting the mTOR signaling pathway to reduce protein synthesis.
Data Source
AI summary
A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and transdermal administration.